Nanobiotix Spon Ads Each Rep 1 Ord Shs (NBTX) Stock
Clinical biotech company enhancing radiation treatment for cancer. Here's the price, business snapshot, and what's worth knowing about Nanobiotix Spon Ads Each Rep 1 Ord Shs in September 2026.
Nanobiotix SA (ADR: NBTX) is a clinical-stage biotechnology company focused on physics-based therapeutics that enhance radiotherapy for solid tumours. Its lead candidate, NBTXR3 (marketed as Hensify in some jurisdictions), are tumour-injected crystalline nanoparticles designed to amplify the local effect of ionising radiation. The company is headquartered in France and listed as an American Depositary Receipt in the US, with multiple Phase II/III programmes and investigator-led studies across indications such as soft-tissue sarcoma and head and neck cancers. As a clinical-stage stock, progress is driven by trial outcomes, regulatory decisions and partnership or commercial execution; revenues are limited and further financing may be required. Market capitalisation is about $1.13bn. This summary is educational only and not personalised investment advice — suitability depends on your circumstances. Remember values can rise and fall and returns are not guaranteed.
About This Stock
NANOBIOTIX SPON ADS EACH REP 1 ORD SHS
NBTX
Current Price
$40.68
Potential 12 Month Profit
-22.92%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
NBTX
Market Cap
$2.14B
Potential 12 Month Profit
-22.92%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Nanobiotix stock, expecting it to rise towards a target price of $31.32.
Financial Health
NANOBIOTIX is generating modest revenue and cash flow, indicating a stable financial situation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Several ongoing trials may provide meaningful data points that could de‑risk the story, though outcomes are binary and timelines can be long.
Physics-based approach
NBTXR3 amplifies radiotherapy locally and may complement existing cancer treatments; adoption depends on convincing clinical evidence and regulatory acceptance.
Commercial and funding
Limited commercial approvals and partnerships could support growth, but rollout complexity and potential funding needs are important considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.